Contact
searchSearch
HMP Global
Login

Bipolar Disorders News

Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network
Postpartum mother holding child
News
Postpartum Psychosis Should Be a Distinct Diagnosis, Experts Recommend
11/19/2025
Maria Mantas
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is...
11/19/2025
Psych Congress Network
Covid-19
News
COVID-19 Post-Acute Sequelae More Likely in Patients With Serious Mental Illness
11/03/2025
Jolynn Tumolo
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia,...
11/03/2025
Psych Congress Network
US FDA sign
News
FDA OKs Once Monthly Subcutaneous Risperidone for Bipolar I Disorder
10/20/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug...
10/20/2025
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
DNA puzzle
News
Recent Cohort Study Assesses Genetic Relationships Between Psychotic Disorders
07/23/2025
Maria Mantas
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective,...
07/23/2025
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
Delusion Themes Stay Consistent Across Psychosis Episodes
News
Delusion Themes Stay Consistent Across Psychosis Episodes, Study Finds
08/20/2024
Jolynn Tumolo
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar...
08/20/2024
Psych Congress Network
fda
News
FDA Approves Iloperidone for Acute Treatment of Bipolar I Disorder
04/08/2024
Meagan Thistle
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for...
04/08/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use